CANTARGIA AB
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 22
- Market Cap
- -
- Website
- http://cantargia.com
Clinical Trials
21
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (21 trials with phase data)• Click on a phase to view related trials
A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis.
- Conditions
- HealthyPlaque Psoriasis
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Cantargia AB
- Target Recruit Count
- 80
- Registration Number
- NCT06143371
- Locations
- 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer.
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Cantargia AB
- Target Recruit Count
- 117
- Registration Number
- NCT05181462
- Locations
- 🇪🇸
Hospital Universitario Virgen de las Nieves, Granada, Andalucía, Spain
🇪🇸Hospital Universitario Clinico San Cecilio, Granada, Andalucía, Spain
🇪🇸Complejo Hospitalario de Jaén, Jaén, Andalucía, Spain
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
- Conditions
- Biliary Tract CancerNon Small Cell Lung CancerColorectal CancerAdvanced Solid Tumors
- Interventions
- Drug: CAN04 (nadunolimab)Drug: DTXDrug: G/CDrug: mFOLFOX
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Cantargia AB
- Target Recruit Count
- 40
- Registration Number
- NCT05116891
- Locations
- 🇫🇷
EDOG Institut de Cancerologie de l'Ouest - PPDS, Saint-Herblain, Boulevard Jacques Monod, France
🇫🇷Centre Georges François Leclerc, Dijon, Côte-d'Or, France
🇫🇷Institut Bergonie, Bordeaux Cedex, France
A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Cantargia AB
- Target Recruit Count
- 25
- Registration Number
- NCT04990037
- Locations
- 🇫🇷
EDOG - Institut Bergonie - PPDS, Bordeaux, France
🇫🇷EDOG Institut de Cancerologie de l'Ouest - PPDS, Nantes, France
🇫🇷EDOG - Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer - PPDS, Rennes, France
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
- Conditions
- Carcinoma, Non-Small-Cell LungUrothelial CarcinomaHead and Neck Squamous Cell CarcinomaMalignant Melanoma
- Interventions
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Cantargia AB
- Target Recruit Count
- 19
- Registration Number
- NCT04452214
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Florida Cancer Specialists & Research Institute, Lake Mary, Florida, United States
🇺🇸Hospital of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Prev
- 1
- 2
- Next
News
Otsuka Pharmaceutical Acquires Cantargia's CAN10 Antibody Program for $33 Million Upfront in Autoimmune Disease Deal
Otsuka Pharmaceutical has acquired worldwide rights to Cantargia's CAN10, an IL-1RAP targeting monoclonal antibody in Phase 1 development for autoimmune diseases, for $33 million upfront.